BMP portfolio company, COTA, Inc., an oncology real-world data and analytics company, announced today that Miruna Sasu, Ph.D., MBA, has been appointed president and chief executive officer. In her new role, she will spearhead efforts to drive broader adoption of real-world data by the life sciences industry to safely accelerate the speed of development and reduce the cost of life-saving cancer drugs. Sasu will also prioritize strategic provider and clinical research partnerships that will support evidence-based standards of care to improve patient outcomes, build health equity for all cancer patients, and drive down costs of cancer care.
Sasu joined COTA in April of 2021 as chief strategy officer and has already started building momentum for the company. She brought extensive experience in senior leadership roles at notable life sciences companies such as Johnson & Johnson and Bristol Myers Squibb.
Read Full Release
Boston Millennia Partners IV is pleased to announce its investment in Pluto Health as part of a growth equity financing round. Pluto Health is an early stage spin out of Duke University improving health care delivery and research. Pluto delivers treatment plans from curated recommendations to close health gaps to access to research, through their proprietary data interoperability and clinical intelligence platform.
Read Full Release
Boston Millennia Partners IV is pleased to announce its investment in Huma.AI as part of a growth equity financing round. Huma.AI is an early-stage, knowledge automation company for the life sciences industry. The Company’s central business is a unified, question-and-answer-based Natural Language Processing (NLP) platform that generates commercial and clinical insights using structured and unstructured data sources. The platform can answer complex questions through the simultaneous analysis of multiple siloed data sets, both public and private. The Company’s customizable SaaS offering can be deployed to address numerous use cases including: competitive intelligence on drug development pipelines, clinical trial design, and post-market surveillance. The company has contracts with over ten top-tier pharma clients.
Read Full Release
SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that it has completed its business combination with CM Life Sciences II, Inc. (Nasdaq: CMIIU), a special purpose acquisition company sponsored by affiliates of leading healthcare and life sciences fund advisors Casdin Capital and Corvex Management. Following the transaction, the combined company was renamed SomaLogic, Inc., and its Class A common stock and warrants will begin trading on the Nasdaq Global Market (“Nasdaq”) on September 2, 2021 under the symbols “SLGC” and “SLGCW,” respectively. The business combination and concurrent private placement were approved by CM Life Sciences II shareholders at its special meeting held on August 31st, 2021.SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that it has completed its business combination with CM Life Sciences II, Inc. (Nasdaq: CMIIU), a special purpose acquisition company sponsored by affiliates of leading healthcare and life sciences fund advisors Casdin Capital and Corvex Management. Following the transaction, the combined company was renamed SomaLogic, Inc., and its Class A common stock and warrants will begin trading on the Nasdaq Global Market (“Nasdaq”) on September 2, 2021 under the symbols “SLGC” and “SLGCW,” respectively. The business combination and concurrent private placement were approved by CM Life Sciences II shareholders at its special meeting held on August 31st, 2021.
Read Full Release
Pharmaceutical researchers are turning to technology to broaden access to experimental treatments, and make clinical trials more equitable in terms of their inclusion of minorities
Minorities are often underrepresented as participants in studies of new drugs—leaving them with less access to new, potentially lifesaving drugs, and making scientists less aware of how medicines affect people of various races differently. One reason is minority groups, because of abuses in the past, sometimes distrust the medical system. Minorities also can lack the resources needed to travel or fulfill other requirements to be able to participate in drug trials.
Read Full Release
Clinical Research IO (CRIO), a Boston-based technology firm offering clinical research sponsors and sites a platform to streamline clinical trials, announced the completion of a $3.5 million Series A round led by Rally Ventures.
The round allows CRIO to expand its product and engineering teams to develop the next wave of products. "Our goal has always been to streamline clinical research," said Raymond Nomizu, company co-founder and CEO. "To do this, we need to ramp up our product and engineering teams. We have laid the groundwork with our unparalleled site network of electronic adopters, and now we want to leverage this to unlock efficiencies for sponsors and contract research organizations (CROs)."
Read Full Release
medaptus today announced that its professional charge capture and charge reconciliation solution, Charge Pro, has again achieved the #1 Mobile Charge Capture ranking in the annual "Best in KLAS: Software & Services" report. medaptus has earned this distinction for the past eleven out of 12 years.
For the 2021 report, the company's top-ranking score of 94.7 is based on customer feedback obtained in the year 2020 across measures such as product quality, value, and support. Charge Pro customers, some of which have been working with company for nearly 20 years, include single-specialty practices, hospital medicine teams, and larger provider entities such as IDNs. More complex entities often rely on medaptus for its unparalleled integration capabilities in order to normalize disparate data sources for full revenue cycle transparency.
Read Full Release
Cecelia Health, a leading virtual health company that empowers people with diabetes and chronic conditions to live better and healthier lives, today announced that it has appointed industry veteran Mark Clermont to succeed founder David Weingard as Cecelia’s Chief Executive Officer. Clermont’s demonstrated leadership and healthcare expertise will help Cecelia Health accelerate and further scale adoption of the company's technology-enabled expert clinical, digital telehealth, and telemedicine solutions. Weingard will transition to his new role as Executive Chairman of the Board where he will continue to support the company on corporate strategy, brand awareness and developing long-term executive relationships.
Read Full Release
LifeScan, a world leader in blood glucose monitoring, serving 20 million people with diabetes and the maker of the iconic OneTouch® brand products, and Cecelia Health, one of the nation's most scalable clinical coaching and telehealth companies focused on diabetes and other chronic disease management, today announced a partnership to deliver best-in-class, live, personalized coaching from Cecelia Health's Certified Diabetes Care and Education Specialists through our OneTouch Reveal app beginning November 2020.
Read Full Release
Patients participating in The Leukemia & Lymphoma Society’s (LLS) groundbreaking precision medicine Beat AML Master Clinical Trial had superior outcomes compared to acute myeloid leukemia (AML) patients who opted for standard chemotherapy treatment, according to findings published today in the prestigious Nature Medicine journal.
The Beat AML trial achieved its primary endpoint by showing genomic analysis of the leukemia cells to identify AML subtypes can be completed within an unprecedented seven days, giving patients, caregivers and their doctors ample time to make a more personalized treatment decision without risking the patient’s chance for survival.
Read Full Release
